Reaffirms FY24 R&D expenses $30M-$36M and SG&A expenses $45M-$55M, in each case excluding share-based compensation; full year share-based compensation expenses $18M-$22M. Sees levels of both non-GAAP losses and cash burn in the second half to be similar to first half actuals 2024.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Theravance Biopharma sees FY24 R&D expenses $30M-36M
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App